Bio-Techne CEO delivers or withholds 2,385 shares
The chief executive officer also reported direct options covering 90,441 common shares at a $53.60 exercise price, expiring August 15, 2035.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BIO-TECHNE Corp Chief Executive Officer Kim Kelderman reported 2,385 common shares delivered or withheld on November 1, 2026, for payment of exercise price or tax liability, at a reported price of $72.66 per share. The directly held common-stock position following the transaction was 80,509 shares. Of the listed performance restricted stock units, 51,261 vest in full or part on August 15, 2027, and 70,708 on August 15, 2028, if certain performance goals are achieved or at a later date when certified by the Administrator.
Insider Trade Summary
Exercise Price or Tax Liability: 2,385 shares
Exercise Price or Tax Liability
1 txn
Insider
Kelderman Kim
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 2,385 | $72.66 | $173K |
| Holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| Holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| Holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| Holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| Holding | Stock Options (Right to Buy) F2 | -- | -- | -- |
| Holding | Stock Options (Right to Buy) F3 | -- | -- | -- |
| Holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| Holding | Stock Options (Right to Buy) F4 | -- | -- | -- |
| Holding | Stock Options (Right to Buy) F5 | -- | -- | -- |
| Holding | Stock Options (Right to Buy) F6 | -- | -- | -- |
| Holding | Performance Restricted Stock Units F7, F8 | -- | -- | -- |
| Holding | Performance Restricted Stock Units F7, F9 | -- | -- | -- |
| Holding | Restricted Stock Units F7, F10 | -- | -- | -- |
| Holding | Restricted Stock Units F7, F11 | -- | -- | -- |
| Holding | Restricted Stock Units F7, F12 | -- | -- | -- |
| Holding | Restricted Stock Units F7, F13 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 80,509 shares (Direct);
Stock Option (Right to Buy) — 141,668 contracts (Direct);
Stock Options (Right to Buy) — 311,808 contracts (Direct);
Performance Restricted Stock Units — 121,969 contracts (Direct);
Restricted Stock Units — 183,285 contracts (Direct)
Footnotes (13)
- F1. Fully exercisable.
- F2. Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
- F3. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
- F4. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
- F5. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
- F6. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
- F7. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F8. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F9. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F10. 8,544 restricted stock units vest on 8/15/2027.
- F11. 11,785 restricted stock units vest on 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
- F12. 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029.
- F13. 93,582 restricted stock units vest on 8/17/2029.
Key Figures
Shares delivered or withheld: 2,385 shares
Reported price per share: $72.66 per share
Direct common shares following transaction: 80,509 shares
+3 more
6 metrics
Shares delivered or withheld
2,385 shares
November 1, 2026; payment of exercise price or tax liability
Reported price per share
$72.66 per share
November 1, 2026 transaction
Direct common shares following transaction
80,509 shares
After the November 1, 2026 transaction
Underlying common shares in direct options
90,441 shares
Options with a $53.60 exercise price, expiring August 15, 2035
Option exercise price
$53.60 per share
Direct options covering 90,441 common shares
Option expiration date
August 15, 2035
Direct options covering 90,441 common shares
Key Terms
Stock Option (Right to Buy), Restricted Stock Units, contingent right, performance goals
4 terms
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"a contingent right to receive one share of Bio-Techne common stock"
performance goals financial
"if certain performance goals are achieved"
Performance goals are specific, measurable targets a company sets for financial results, operational milestones, or individual roles—examples include revenue, profit, production levels, or completion of a project. They matter to investors because meeting or missing these targets influences management pay, future forecasts, deal-related payments and market confidence; think of them as a scoreboard that helps outsiders judge whether the business is performing as promised.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When do Kim Kelderman's reported TECH restricted stock units vest?
A reported position of 57,590 restricted stock units is scheduled to vest in installments of 19,197 on August 17, 2027, 19,197 on August 17, 2028, and 19,196 on August 17, 2029. A separate position of 93,582 restricted stock units is scheduled to vest on August 17, 2029.
AI-generated analysis. How Rhea-AI works. Not financial advice.
